IDiyas

For the Inventor, By the Inventor

Durmenach, France

Nicolas Zorn

USPTO Granted Patents = 13 

 

Average Co-Inventor Count = 13.1

ph-index = 1

Forward Citations = 34(Granted Patents)


Location History:

  • Short Hills, NJ (US) (2012 - 2014)
  • Fanwood, NJ (US) (2016 - 2017)
  • Durmenach, FR (2016 - 2018)

Company Filing History:

goldMedal13 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal1 out of 97 
 
Albany Molecular Research, Inc.
 patents
bronzeMedal1 out of 7 
 
Msd Italia S.r.l.
 patents
where one patent can have more than one assignee

Years Active: 2012-2018

Loading Chart...
Loading Chart...
13 patents (USPTO):
1. 10011615 - Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties (2018-07-03),
2. 9840478 - Piperazine derivatives as HIV protease inhibitors (2017-12-12),
3. 9676780 - [object Object] (2017-06-13),
4. 9549921 - Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C (2017-01-24),
5. 9549917 - Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases (2017-01-24),
6. 9493461 - Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C (2016-11-15),
7. 9364482 - Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases (2016-06-14),
8. 9265773 - Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases (2016-02-23),
9. 9243002 - Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C (2016-01-26),
10. 9242998 - Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C (2016-01-26),
11. 8716312 - Inhibitors of diacylglycerol acyltransferase (2014-05-06),
12. 8637507 - Bicyclic compounds as inhibitors of diacylglycerol acyltransferase (2014-01-28),
13. 8232274 - Pyridazinone derivatives useful as glucan synthase inhibitors (2012-07-31),

Title: The Innovative Mind of Nicolas Zorn

Introduction: Nicolas Zorn, an accomplished inventor based in Durmenach, France, holds a remarkable portfolio of 13 patents. His work primarily focuses on pharmaceuticals, with innovations aimed at tackling significant health issues, including neurological disorders and HIV.

Latest Patents: Among Zorn's latest inventions are two notable patents. The first relates to "Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A antagonist properties." This invention discloses compounds with the potential to serve as antagonists of the A2A receptor, which play a crucial role in various neurological disorders. The second patent involves "Piperazine derivatives as HIV protease inhibitors," focusing on novel compounds that may inhibit HIV protease and consequently help in treating HIV infections and AIDS.

Career Highlights: Zorn's career includes significant contributions while working at renowned companies like Merck Sharp & Dohme Corporation and Albany Molecular Research, Inc. His research and innovations have significantly impacted the pharmaceutical landscape, potentially advancing treatment options for pressing medical conditions.

Collaborations: Throughout his career, Zorn has collaborated with talented colleagues, such as Dong Xiao and Peng Li. These partnerships have likely played a crucial role in the development and refinement of his innovative ideas and products, enhancing their efficacy and application.

Conclusion: In summary, Nicolas Zorn stands out as a prominent inventor whose patents reflect a commitment to improving health outcomes through innovative pharmaceutical solutions. His work exemplifies the spirit of innovation necessary to tackle complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…